<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03819777</url>
  </required_header>
  <id_info>
    <org_study_id>NL57351.068.17</org_study_id>
    <nct_id>NCT03819777</nct_id>
  </id_info>
  <brief_title>Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)</brief_title>
  <acronym>VOC-PAH</acronym>
  <official_title>Volatile Organic Compounds as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: to investigate the role of inflammation and auto-immunity in pulmonary arterial&#xD;
      hypertension by using the profile of volatile organic compounds.&#xD;
&#xD;
      Hypothesis: first, the investigators hypothesize that at time of diagnosis the VOC profiles&#xD;
      will discriminate patients with PAH-CTD and idiopathic PAH (IPAH) from patients with systemic&#xD;
      sclerosis or systemic lupus erythematosus (CTD) without PAH, supporting the contention that&#xD;
      there is a overlapping inflammatory and auto-immune pathway in PAH. During follow-up, the&#xD;
      investigators will measure the VOC profiles of patients in all three groups who will be&#xD;
      treated according standard clinical care. The hypothesis is that VOC profiles are affected by&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determining unique inflammatory VOC profiles in exhaled air in three groups of patients: IPAH, PAH-CTD and CTD without PAH.</measure>
    <time_frame>3 measurements in 2 weeks</time_frame>
    <description>Exhaled air samples will be analyzed on inflammatory VOC profiles in the diagnostic phase of the study. Three measurements over a period of two weeks will be done. Statistically analysis will report one average VOC profile of the three measurements.&#xD;
Procedure: the patient is asked to exhale via a sterile mask into the ReCIVA breath sampler (Owlstone Medical, Cambridge, UK) in which mixed total exhaled air is immediately trapped and stored onto stainless-steel two-bed sorption tubes, filled with carbograph 1TD/Carbopack X (Markes International, Wales, UK). The tubes will be analyzed with GC-TOF-MS for the presence of VOCs after which multivariate statistical analysis will be used to select those VOCs unique for the various patient groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between unique inflammatory VOCs to well-established biomarkers of immune activation and inflammation in PAH-CTD and idiopathic PAH.</measure>
    <time_frame>1 measurement at baseline</time_frame>
    <description>The correlation analysis by means of bivariate (Spearman correlation) and multivariate analysis (canonical correlation analysis) will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change (Δ, delta) from baseline in selective inflammatory VOC profiles after 3, 6 and 12 months in all patients treated with PAH and/or immunsuppressive medication.</measure>
    <time_frame>Changes (Δ, delta) between baseline, 3 months, 6 months, 9 months and 12 months</time_frame>
    <description>Wilcoxon signed-rank test will be utilized to see if the individual, selective inflammatory VOCs after treatment significantly differ with the baseline measurements.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Systemic Sclerosis</condition>
  <condition>Systemic Lupus</condition>
  <arm_group>
    <arm_group_label>Idiopathic PAH</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>CTD-PAH</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>CTD without PAH</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood exhaled air&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        See eligibility criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. PAH-CTD patients, inclusion criteria:&#xD;
&#xD;
               -  classification as definite systemic sclerosis or systemic lupus erythematosus&#xD;
                  according to respectively the ACR-EULAR criteria (16) and SLICC criteria (17)&#xD;
&#xD;
               -  minimal age of 18 year&#xD;
&#xD;
               -  diagnosis of pulmonary arterial hypertension: mean pulmonary artery pressure&#xD;
                  (mPAP) of ≥25 mmHg, pulmonary capillary wedge pressure (PCWP) ≤15 mmHg, and a&#xD;
                  pulmonary vascular resistance (PVR) ≥240 dynes.s.cm-5 measured by right heart&#xD;
                  catherization.&#xD;
&#xD;
          2. IPAH patients, inclusion criteria:&#xD;
&#xD;
               -  diagnosis of pulmonary arterial hypertension: mean pulmonary artery pressure&#xD;
                  (mPAP) of ≥25 mmHg, pulmonary capillary wedge pressure (PCWP) ≤15 mmHg, and a&#xD;
                  pulmonary vascular resistance (PVR) ≥240 dynes.s.cm-5 measured by right heart&#xD;
                  catherization.&#xD;
&#xD;
               -  no family history of PAH&#xD;
&#xD;
               -  triggering factor is excluded: connective tissue disease, drugs or toxins, human&#xD;
                  immunodeficiency virus, congenital heart disease, portal hypertension,&#xD;
                  schistosomiasis (2)&#xD;
&#xD;
               -  minimal age of 18 year&#xD;
&#xD;
          3. SSc and SLE (CTD) patients without PAH, inclusion criteria:&#xD;
&#xD;
               -  classification as definite systemic sclerosis or systemic lupus erythematosus&#xD;
                  according to respectively the ACR-EULAR criteria (16) and SLICC criteria (17)&#xD;
&#xD;
               -  minimal age of 18 year&#xD;
&#xD;
               -  no signs of PAH at screening visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  active or treated malignancy&#xD;
&#xD;
          -  tuberculosis or hepatitis B/C infection in case of start immunosuppressive therapy&#xD;
&#xD;
          -  need to start immediately with therapy&#xD;
&#xD;
          -  already use of immune suppression&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pieter van Paassen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judith Potjewijd, MD</last_name>
    <phone>+31 (0) 433871198</phone>
    <email>pah.uitademingslucht.int@mumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Potjewijd, MD</last_name>
      <phone>+31-(0)43-3871198</phone>
      <email>pah.uitademingslucht.int@mumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2019</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

